Medtronic also recently teamed with Tempus to assess the use of artificial intelligence to identify people eligible for ...
Medical device giant Medtronic has shared data from the SMART trial showing that its Evolut transcatheter aortic valve replacement (TAVR) system is superior for treating aortic stenosis in ...
Wednesday, the FDA approved Medtronic plc’s (NYSE:MDT) Evolut FX+ transcatheter aortic valve replacement (TAVR) system for symptomatic severe aortic stenosis. The latest Evolut FX+ TAVR system ...
Medtronic, a leader in medical technology and Philips, a leader in health technology announced the signing of a Memorandum of ...
The first human TAVR was performed by Dr. Cribier in 2002 ... but not yet approved by the FDA, is the Medtronic CoreValve. It also has gone through three generations of design improvements.
(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.
Structural heart products, including the Evolut FX+ TAVR system, showed high-single ... in Hugo robotics and Affera ablation systems. Medtronic reported strong Q3 results, driven by cardiovascular ...